Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'-Deoxy-2'-fluoroadenosine is a modified nucleoside analog and small molecule antimetabolite characterized by the substitution of a fluorine atom at the 2' position of the ribose sugar. It functions as a prodrug in suicide gene therapy systems, where it is selectively cleaved by *Escherichia coli* purine nucleoside phosphorylase (PNP) to release the highly cytotoxic agent 2-fluoroadenine. This metabolite inhibits DNA and RNA synthesis, leading to cell death in both proliferating and quiescent cells, a property utilized to treat solid tumors expressing the bacterial PNP gene. Beyond oncology, the compound and its derivatives have been investigated for antiviral activity against a range of RNA and DNA viruses, including Hepatitis C virus (HCV), HIV, SARS-CoV, and influenza, often acting as a viral polymerase inhibitor or chain terminator. It is also widely employed as a research tool in the synthesis of modified oligonucleotides to investigate nucleic acid structure and protein-nucleic acid interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2'-deoxy-2'-fluoroadenosine.